-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Tempest Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2012 to 2024.
- Tempest Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$13.9M, a 85.2% decline year-over-year.
- Tempest Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$42M, a 44.1% decline year-over-year.
- Tempest Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$42M, a 44.1% decline from 2023.
- Tempest Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$29.2M, a 15.8% increase from 2022.
- Tempest Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$34.6M, a 28.4% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)